Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Jul 27, 2021 2:24pm
62 Views
Post# 33611160

RE:Owning this stock is akin to cheering for the Leafs

RE:Owning this stock is akin to cheering for the Leafs

Not everything you see is what it appears to be...


10,968,852 ($2,231,611) PMN.TO shares exchanged hands from Sun Jun 27 2021 to Tue Jul 27 2021.

House  Bought  Sold  Net 
House 022
Fidelity
Bought $402,587
Volume 2,018,000
Average $0.199
Sold $10,284
Volume 49,000
Average $0.210
Net $392,303
Volume 1,969,000
 
House 068
Leede
Bought $318,991
Volume 1,584,500
Average $0.201
Sold 0
Volume 0
Average 0
Net $318,991
Volume 1,584,500
 
House 080
National Bank
Bought $163,456
Volume 777,300
Average $0.210
Sold $67,739
Volume 337,616
Average $0.201
Net $95,717
Volume 439,684
 
House 089
Raymond James
Bought $86,910
Volume 405,600
Average $0.214
Sold 0
Volume 0
Average 0
Net $86,910
Volume 405,600
 
House 079
CIBC
Bought $108,100
Volume 548,336
Average $0.197
Sold $47,122
Volume 232,650
Average $0.203
Net $60,978
Volume 315,686
 
House 014
ITG
Bought $48,171
Volume 222,450
Average $0.217



quote=BottomBroker]Just when you think there's a glimmer of hope, a chance for something big....BLAM! Back to the  drawing board. [/quote]
 


10,968,852 ($2,231,611) PMN.TO shares exchanged hands from Sun Jun 27 2021 to Tue Jul 27 2021.
House  Bought  Sold  Net 
House 022
Fidelity
Bought $402,587
Volume 2,018,000
Average $0.199
Sold $10,284
Volume 49,000
Average $0.210
Net $392,303
Volume 1,969,000
 
House 068
Leede
Bought $318,991
Volume 1,584,500
Average $0.201
Sold 0
Volume 0
Average 0
Net $318,991
Volume 1,584,500
 
House 080
National Bank
Bought $163,456
Volume 777,300
Average $0.210
Sold $67,739
Volume 337,616
Average $0.201
Net $95,717
Volume 439,684
 
House 089
Raymond James
Bought $86,910
Volume 405,600
Average $0.214
Sold 0
Volume 0
Average 0
Net $86,910
Volume 405,600
 
House 079
CIBC
Bought $108,100
Volume 548,336
Average $0.197
Sold $47,122
Volume 232,650
Average $0.203
Net $60,978
Volume 315,686
 
House 014
ITG
Bought $48,171
Volume 222,450
Average $0.217

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse